FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology and specifically to a method for modifying a eukaryotic cell in vitro or ex vivo. Method involves delivery into a eukaryotic cell of a CRISPR-Cas system containing a Cas type V protein containing a RuvC domain, but not an HNH domain, or a nucleic acid coding this Cas type V protein, and a CRISPR-Cas guide polynucleotide designed for hybridisation with a target sequence of a genomic locus of interest in a eukaryotic cell, or a nucleic acid coding the CRISPR-Cas guide polynucleotide.
EFFECT: invention is effective for eukaryotic cell modification in vitro or ex vivo.
24 cl, 116 dwg, 10 tbl, 19 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL ENZYMES AND CRISPR SYSTEMS | 2016 |
|
RU2737537C2 |
| NEW ENZYMES AND CRISPR SYSTEMS | 2016 |
|
RU2777988C2 |
| NEW CRISPR ENZYMES AND SYSTEMS | 2016 |
|
RU2771826C2 |
| SYSTEM DESIGN, METHODS AND OPTIMIZED GUIDE COMPOSITIONS FOR SEQUENCE MANIPULATION | 2013 |
|
RU2796017C2 |
| COMPOSITIONS AND METHODS OF GENE EDITING | 2019 |
|
RU2804665C2 |
| ESCHERICHIA COLI BL21(DE3)PLYSS/PET15B-HISCPF1 STRAIN: PRODUCER OF RNA-GUIDED ENDONUCLEASE CRISPR/CPF1 | 2021 |
|
RU2774120C1 |
| COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | 2017 |
|
RU2795467C2 |
| COMPONENTS OF THE CRISPR-CAS SYSTEM, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION | 2013 |
|
RU2796549C2 |
| NON-VIRAL IMMUNOTARGETING | 2020 |
|
RU2833379C2 |
| DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST LYME DISEASE | 2017 |
|
RU2813829C2 |
